A study in the British Journal of Cancer reported that whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict treatment outcomes for advanced ovarian cancer following neoadjuvant chemotherapy. Researchers evaluated imaging signals after NACT and linked them to subsequent clinical endpoints. Whole-body MRI could help clinicians refine post-chemotherapy decision-making by providing a noninvasive, whole-patient view rather than relying solely on localized assessment. The results add to expanding efforts to use imaging biomarkers to improve staging accuracy and prognosis in ovarian cancer, where treatment response can vary substantially across patients.